Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Grace Watson"'
Autor:
Grace Watson, Jeong Eun Ahn
Publikováno v:
Applied Sciences, Vol 12, Iss 23, p 12331 (2022)
This study investigated literature databases of Google Scholar and Scopus from 1900 to 2021 and reviewed relevant studies conducted to increase transportation infrastructure resilience to flood events. This review has three objectives: (1) determine
Externí odkaz:
https://doaj.org/article/21cec502fa5f456d94b9eaf127932b58
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy and other therapeutic immune effector cel
Externí odkaz:
https://doaj.org/article/fdc3d6c1b285470699cabcc1a72c160b
Autor:
Xubin Li, Qing Deng, Jared Henderson, Grace Watson, Laurel Deaton, Taylor Cain, Luis Fayad, Swaminathan Padmanabhan Iyer, Fredrick B. Hagemeister, Loretta J. Nastoupil, Nathan H. Fowler, Jason Westin, Raphael Steiner, Ranjit Nair, Sairah Ahmed, Gheath Alatrash, Sattva S. Neelapu, Paolo Strati, Michael R Green
Publikováno v:
Blood. 140:4502-4503
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b9c4a5f79b6f5a7bc682dbaf63eb7eb
https://doi.org/10.1182/blood-2022-166308
https://doi.org/10.1182/blood-2022-166308
Autor:
Sattva S. Neelapu, Bouthaina S. Dabaja, Michael W. Morrison, Felipe Samaniego, Linda Chi, Paolo Strati, Raphael E Steiner, Luis Fayad, Chelsea C. Pinnix, Philip A. Thompson, Grace Watson, Rashmi Kanagal-Shamanna, Fateeha Furqan, Loretta J. Nastoupil
Publikováno v:
Leuk Lymphoma
Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin Lymphoma (NHL) that can be further classified into 3 sub-types: nodal, extra-nodal and splenic [1]. MZL rarely involves the central ne...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::457452c3bfabc102fb41375b4abff629
https://doi.org/10.1080/10428194.2020.1791849
https://doi.org/10.1080/10428194.2020.1791849
Autor:
Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali K. Kamdar, Brian Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Yi Lin, Madiha Iqbal, Reid W. Merryman, Paolo Strati
Publikováno v:
Blood advances. 6(9)
Polatuzumab vedotin (PV) is an antibody–drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27781793ac01668ca93b7f41b09950e
https://pubmed.ncbi.nlm.nih.gov/35240681
https://pubmed.ncbi.nlm.nih.gov/35240681
Autor:
Ajlan Al Zaki, Lei Feng, Grace Watson, Sairah A. Ahmed, Haleigh Mistry, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P. Iyer, Hun J. Lee, Raphael E. Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Jason R. Westin, Paolo Strati
Publikováno v:
Blood advances. 6(9)
About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)–computed tomography
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0885cea279f59f23e43f559b37e052f9
https://pubmed.ncbi.nlm.nih.gov/35015825
https://pubmed.ncbi.nlm.nih.gov/35015825
Autor:
Paolo Strati, Allison Rosenthal, Sushanth Gouni, Jennifer Crombie, Andrew Ip, Manali Kamdar, Brian Hess, Lei Feng, Grace Watson, Amy Ayers, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid Merryman, Sattva S. Neelapu
Publikováno v:
Transplantation and Cellular Therapy. 28:S405-S406
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7776024c58a1bf72037131d4d24e6c5
https://doi.org/10.1016/s2666-6367(22)00678-9
https://doi.org/10.1016/s2666-6367(22)00678-9
Publikováno v:
Journal of visualized experiments : JoVE. (173)
Ischemia-reperfusion injury (IRI) is the leading cause of acute renal failure and is a significant contributor to delayed graft function. Animal models are the only available resources that mimic the complexities of the IRI-associated damage encounte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6385475bbfcb8cd1c20ec02df4ac85fe
https://pubmed.ncbi.nlm.nih.gov/34338680
https://pubmed.ncbi.nlm.nih.gov/34338680
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy and other therapeutic immune effector cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c49af2d06dec7a3bfc9818353aaada
https://doi.org/10.3389/fonc.2020.00885
https://doi.org/10.3389/fonc.2020.00885
Autor:
Allison C. Rosenthal, Madiha Iqbal, Amy Ayers, Manali Kamdar, Brian T. Hess, Lei Feng, Arushi Khurana, Sattva S. Neelapu, Yi Lin, Sushanth Gouni, Reid W. Merryman, Paolo Strati, Andrew Ip, Jennifer L. Crombie, Grace Watson
Publikováno v:
Blood. 138:2495-2495
Introduction. About 60% of patients with large B-cell lymphoma (LBCL) relapse after standard of care (SOC) anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy, CD19 downregulation representing a major mechanism of resistance. Therefor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0076883e17e91933f15a7366c6cec834
https://doi.org/10.1182/blood-2021-147591
https://doi.org/10.1182/blood-2021-147591